TY  - JOUR
AU  - Powles, Thomas
AU  - Duran, Ignacio
AU  - van-der-Heijden, Michiel S
AU  - Loriot, Yohann
AU  - Vogelzang, Nicholas J
AU  - De-Giorgi, Ugo
AU  - Oudard, Stephane
AU  - Retz, Margitta M
AU  - Castellano, Daniel
AU  - Bamias, Aristotelis
AU  - Flechon, Aude
AU  - Gravis, Gwenaëlle
AU  - Hussain, Syed
AU  - Takano, Toshimi
AU  - Leng, Ning
AU  - Kadel, Edward E
AU  - Banchereau, Romain
AU  - Hegde, Priti S
AU  - Mariathasan, Sanjeev
AU  - Cui, Na
AU  - Shen, Xiaodong
AU  - Derleth, Christina L
AU  - Green, Marjorie C
AU  - Ravaud, Alain
PY  - 2017
DO  - 10.1016/S0140-6736(17)33297-X
UR  - http://hdl.handle.net/10668/11939
T2  - Lancet (London, England)
AB  - Few options exist for patients with locally advanced or metastatic urothelial carcinoma after progression with platinum-based chemotherapy. We aimed to assess the safety and efficacy of atezolizumab (anti-programmed death-ligand 1 [PD-L1]) versus...
LA  - en
PB  - The Lancet Publishing Group
KW  - Antibodies, Monoclonal
KW  - Aged
KW  - Antineoplastic Agents
KW  - Docetaxel
KW  - Middle Aged
KW  - Taxoids
KW  - Urologic Neoplasms
KW  - Adult
KW  - Aged, 80 and over
KW  - Antibodies, Monoclonal, Humanized
KW  - Carcinoma
KW  - Female
KW  - Humans
KW  - Male
KW  - Paclitaxel
KW  - Treatment Outcome
KW  - Vinblastine
TI  - Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.
TY  - research article
VL  - 391
ER  -